Modified peptide as well as cosmetic composition or medicinal composition and application thereof
By changing the functional groups of the peptide, the modified peptide TM-1 with hydrophobic groups is designed, which solves the problem that bioactive peptides are difficult to cross the skin cell membrane, achieves enhanced skin permeability and anti-aging effects, and demonstrates moisturizing, firming and Remarkable effects of anti-wrinkle.
Patent Information
- Application Number
- CN202411225079.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-03
- Publication Date
- 2024-12-03
AI Technical Summary
Due to the molecular size, polarity and hydrophilicity of existing bioactive peptides, it is difficult for them to cross the skin cell membrane, resulting in limited anti-skin aging effect.
By changing the functional groups of the parent peptide, using a combination strategy of hydrophobic groups, a modified peptide (TM-1) is designed to enhance its permeability to lipids between stratum corneum cells and promote fibroblast proliferation and keratinocytes by promoting fibroblast proliferation and keratinocytes Formulate and improve skin permeability.
This modified peptide significantly reduces ROS production in HSF cells and has moisturizing, nourishing, firming and anti-wrinkle effects, and is used to treat and prevent signs of skin aging and photoaging.
Smart Images

Figure CN119060120A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of chemical technology, and in particular to a modified peptide and a cosmetic composition or a pharmaceutical composition and application thereof. Background Art
[0002] The skin is an important barrier, conduction and excretion organ of the human body. Skin aging is a complex process that is affected by both internal and external factors. According to these influencing factors, skin aging can be mainly divided into two types: intrinsic aging (also called natural aging or intrinsic aging) and extrinsic aging caused by external stimuli.
[0003] Among external aging, ultraviolet (UV) radiation causes more than 80% of skin aging, so it is also called skin photoaging. The main types of UV rays are UVB, which mainly affects the epidermis, and UVA, which can penetrate the upper dermis and is the main culprit of photoaging. UV exposure increases the production of reactive oxygen species (ROS). These highly reactive chemicals can damage cell membranes, proteins and DNA, leading to cell dysfunction and death, thereby promoting skin aging. At the same time, UV rays also lead to increased cytokine secretion, enhanced antioxidant stress response, and increased expression of matrix metalloproteinases (MMPs). These factors promote the degradation of the extracellular matrix (ECM), the breakage of collagen, and the exacerbation of skin inflammation.
[0004] Skin aging has various manifestations, such as increased wrinkles, sagging, increased elasticity, telangiectasia, and abnormal pigmentation. The clinical manifestations of photoaging include rough skin, dryness, increased wrinkles, decreased elasticity, sagging, telangiectasia, pigmentation, and seborrheic keratosis. In some cases, individuals may even develop benign or malignant skin tumors. Histologically, the epidermis becomes thinner, the number of cells in each layer decreases, and the skin structure becomes irregular or even disappears. In the dermis, the number of fibroblasts and mast cells decreases, ECM degradation increases and synthesis decreases, the ratio of type I and type III collagen changes, and elastic fibers degenerate.
[0005] Bioactive peptides are peptide compounds composed of short-chain amino acids. They not only have a variety of protective functions for the skin, but also can be effectively absorbed by the skin due to their small molecular weight. They are currently widely used in topical preparations to combat skin photoaging. Based on the mechanism of action, bioactive peptides in skin care products can be divided into three types: signal peptides, carrier peptides, and neurotransmitter inhibitory peptides.
[0006] These diverse peptides can be incorporated into skin care products to achieve the goal of treating damaged skin. For example, Argireline is able to block neurotransmitter signaling, thereby achieving more relaxed and smoother skin. Palmitoyl Pentapeptide-4 can regulate fibroblasts and promote the production of extracellular matrix components.
[0007] Although the bioactive peptides (or polypeptides) currently used for skin care can cross the cell membrane, most polypeptides have difficulty crossing the cell membrane due to problems such as molecular size, polarity, hydrophilicity and charge. Therefore, it is necessary to design a polypeptide with stronger permeability. Summary of the invention
[0008] The present invention has been found through research that in order to obtain peptides with poor hydrophilicity, the functional groups of the parent peptide may be changed. The combination strategy of parent peptide + hydrophobic group changes the tendency of peptide substances to tend to the intercellular lipids of the stratum corneum by changing the distribution coefficient, which can enhance skin permeability and enhance the anti-skin aging effect. Therefore, the first purpose of the present invention is to provide a modified anti-aging polypeptide with excellent skin permeability. The second purpose of the present invention is a cosmetic composition or a pharmaceutical composition containing these modified peptides, which can be used to treat, prevent and / or repair signs of skin aging and / or photoaging by promoting fibroblast proliferation, promoting keratinocyte adhesion, and increasing skin elasticity. The third purpose of the present invention is to provide the use of these modified peptides in cosmetic compositions or pharmaceutical compositions.
[0009] In order to achieve the above object, the present invention adopts the following technical solution:
[0010] As a first aspect of the present invention, a modified peptide is represented by the following formula TM-1:
[0011]
[0012] As a second aspect of the present invention, an isolated or synthesized compound comprises a peptide as shown in the above formula TM-1, or a stereoisomer, a mixture of stereoisomers, a cosmetically acceptable salt or a pharmaceutically acceptable salt of the peptide as shown in the above formula TM-1.
[0013] As a third aspect of the present invention, a method for preparing the modified peptide described above comprises the following steps:
[0014]
[0015] Step 1: Substitution reaction of reactant 1-1 with methyl 3-aminopropionate to obtain intermediate 1-2;
[0016] Step 2: adding intermediate 1-2 and lithium hydroxide to a mixed solution of tetrahydrofuran and water to react to obtain intermediate 1-3;
[0017] Step 3: Dissolve the intermediate 1-3, N-hydroxysuccinimide and N,N'-diisopropylcarbodiimide in dichloromethane and react to obtain the intermediate 1-4;
[0018] Step 4: Dissolve the intermediate 1-4, L-proline and triethylamine in ethyl acetate and react to obtain the intermediate 1-5;
[0019] Step 5: Dissolve the intermediate 1-5, N-hydroxysuccinimide and N,N'-diisopropylcarbodiimide in dichloromethane and react to obtain the intermediate 1-6;
[0020] Step 6: Dissolve intermediate 1-6, H-Dab(Boc)-OH and triethylamine in ethyl acetate and react to obtain intermediate 1-7;
[0021] Step 7: Dissolve intermediate 1-7, benzylamine, EDCI and HOAt in ethyl acetate and react to obtain intermediate 1-8;
[0022] Step 8: Add intermediate 1-8 to a mixed solution of dichloromethane and trifluoroacetic acid to prepare compound TM-1.
[0023] According to the present invention, the lithium hydroxide in step 2 can be replaced by a strong alkaline solution such as sodium hydroxide or potassium hydroxide.
[0024] According to the present invention, the dichloromethane in step 3 can be replaced by N,N-dimethylformamide.
[0025] According to the present invention, the temperature of the substitution reaction in step 1 is 30° C.-50° C., and the stirring reaction is for 6-8 hours.
[0026] According to the present invention, the volume ratio of tetrahydrofuran to water in step 2 is 10:1.
[0027] According to the present invention, the volume ratio of dichloromethane to trifluoroacetic acid in the mixed solution of step 8 is 2:1.
[0028] According to the present invention, the molar ratio of reactant 1-1 to methyl 3-aminopropionate in step 1 is 1:1.0-1.3.
[0029] As the fourth aspect of the present invention, a cosmetic composition containing the peptide represented by the above formula TM-1, or a stereoisomer, a mixture of stereoisomers, a cosmetically acceptable salt or a pharmaceutically acceptable salt of the peptide represented by the above formula TM-1, can promote fibroblast proliferation, promote keratinocyte adhesion, increase skin elasticity, and can be used to treat, prevent and / or repair signs of skin aging and / or photoaging.
[0030] As the fifth aspect of the present invention, a pharmaceutical composition containing the peptide represented by the above formula TM-1, or a stereoisomer, a mixture of stereoisomers, a cosmetically acceptable salt or a pharmaceutically acceptable salt of the peptide represented by the above formula TM-1, can promote fibroblast proliferation, promote keratinocyte adhesion, increase skin elasticity, and can be used to treat, prevent and / or repair signs of skin aging and / or photoaging.
[0031] As a sixth aspect of the present invention, a use of the modified peptide in a cosmetic composition or a pharmaceutical composition.
[0032] As the seventh aspect of the present invention, a use of the isolated or synthesized compound described above in a cosmetic composition or a pharmaceutical composition.
[0033] Beneficial effects of the present invention:
[0034] The modified peptide of the present invention can reduce the production of ROS production rate of HSF cells, and has moisturizing, nourishing, firming, anti-wrinkle and firming effects;
[0035] The cosmetic composition or pharmaceutical composition made from the modified peptide of the present invention is mild and non-irritating during treatment and has moisturizing, nourishing, firming and anti-wrinkle effects. BRIEF DESCRIPTION OF THE DRAWINGS
[0036] Figure 1 is the structural formula of compound TM-1 prepared in Example 1.
[0037] Figure 2 and Figure 3 This is the effect of TM-1 in Example 2 on the ROS production rate of HSF cells. DETAILED DESCRIPTION
[0038] In order to enable those skilled in the art to more fully understand the technical solution of the present invention, exemplary embodiments of the present invention will be described in more comprehensive and detailed manner below in conjunction with the accompanying drawings.
[0039] The following examples are used to illustrate the present invention, but are not intended to limit the scope of the present invention. The experimental methods used in the following examples are conventional methods unless otherwise specified. The materials, reagents, etc. used in the following examples, unless otherwise specified, can all be obtained from commercial sources.
[0040] 1. Product Source
[0041] All chemical reagents in the following examples were purchased from Shanghai Titan, Anaiji Chemical and Shanghai Bid.
[0042] Example 1 Preparation of active ingredient TM-1
[0043] The preparation method of active ingredient TM-1 comprises the following steps:
[0044]
[0045] Step 1: The reactant 1-1 (4.23 g), methyl 3-aminopropanoate (2.9 g), EDCI (4.77 g), HOAt (3.38 g) and DIPEA (5.35 g) were dissolved in ethyl acetate (100 mL), and stirred at 40° C. for 8 hours under nitrogen protection. The mixture was extracted three times with saturated aqueous sodium bicarbonate solution, 2% aqueous hydrochloric acid solution and water (80 mL each). The organic phase was dried over anhydrous sodium sulfate and concentrated to dryness under reduced pressure. The crude product was purified by column chromatography to obtain intermediate 1-2 (5.8 g).
[0046] Step 2: Add intermediate 1-2 (5.8 g) and lithium hydroxide (2.3 g) to a mixed solution (60 mL) of tetrahydrofuran and water in a volume ratio of 10:1, stir at room temperature for 2 hours, adjust the pH to 4 with 1 mol / L hydrochloric acid, concentrate under reduced pressure to remove tetrahydrofuran, extract the aqueous phase with ethyl acetate, dry, and concentrate under reduced pressure to obtain intermediate 1-3 (5.66 g).
[0047] Step 3: Dissolve intermediate 1-3 (4.8 g), N-hydroxysuccinimide (2.52 g), and N,N'-diisopropylcarbodiimide (2.76 g) in dichloromethane (50 mL), stir and react at room temperature for 6 hours, filter, and concentrate under reduced pressure to obtain intermediate 1-4 (7.34 g).
[0048] Step 4: Dissolve intermediate 1-4 (7.34 g), L-proline (3.62 g), and triethylamine (3.2 g) in ethyl acetate (80 mL), stir the reaction at room temperature for 10 hours, extract three times with saturated sodium bicarbonate aqueous solution (80 mL), 2% hydrochloric acid aqueous solution (80 mL), and water (80 mL), respectively. Dry the organic phase over anhydrous sodium sulfate, concentrate to dryness under reduced pressure, and obtain intermediate 1-5 (6.1 g) by reverse column chromatography.
[0049] Step 5: Dissolve intermediate 1-5 (6.1 g), N-hydroxysuccinimide (2.30 g), and N,N'-diisopropylcarbodiimide (2.51 g) in dichloromethane (60 mL), stir and react at room temperature for 6 hours, filter, and concentrate under reduced pressure to obtain intermediate 1-6 (6.7 g).
[0050] Step 6: Dissolve intermediate 1-6 (7.34 g), H-Dab(Boc)-OH (4.72 g), and triethylamine (2.2 g) in ethyl acetate (80 mL), stir the reaction at room temperature for 10 hours, extract three times with saturated aqueous sodium bicarbonate solution (80 mL), 2% aqueous hydrochloric acid solution (80 mL), and water (80 mL), respectively. Dry the organic phase over anhydrous sodium sulfate, concentrate to dryness under reduced pressure, and obtain intermediate 1-7 (7.6 g) by reverse column chromatography.
[0051] Step 7: Dissolve intermediate 1-7 (7.60 g), benzylamine (1.82 g), EDCI (3.25 g), and HOAt (2.30 g) in ethyl acetate (100 mL). Stir the mixture at 40 °C for 8 hours under nitrogen protection. Extract the mixture three times with saturated aqueous sodium bicarbonate solution (80 mL), 2% aqueous hydrochloric acid solution (80 mL), and water (80 mL). Dry the organic phase over anhydrous sodium sulfate, and concentrate to dryness under reduced pressure. The crude product is purified by column chromatography to obtain intermediate 1-8 (6.33 g).
[0052] Step 8: Add intermediate 1-8 (300 mg) to a mixed solution (3 mL) of dichloromethane and trifluoroacetic acid in a volume ratio of 2:1, and stir at room temperature for 1 hour. After the reaction is completed, concentrate under reduced pressure to remove trifluoroacetic acid and dichloromethane, dissolve the residue in methanol (3 mL), add ammonia (6 mL), stir for 16 hours to dissociate trifluoroacetate, and concentrate and dissolve in methanol to prepare compound TM-1 (112 mg) by high-performance liquid chromatography.
[0053] The results of HPLC (high performance liquid chromatography) and MS (mass spectrometry) are as follows:
[0054] HPLC: purity 98.56%.
[0055] MS calcd for C 29 H 45 O4N5[M+H3O] + :546.7
[0056] Example 2 Pharmacological Experiment Example Antioxidant Activity Evaluation
[0057] 2.1 Experimental cells: human normal skin fibroblast cell line (HSF).
[0058] 2.2 Main instruments and reagents: CCL-050B-8 carbon dioxide incubator, MiniMax-12+ mini centrifuge, SW-CJ-2FD clean bench, SOP 1 / 10,000 electronic scale, DMI8 fluorescence microscope.
[0059] 2.3 Main experimental reagents: high-glucose DMEM (Dulbecco's Modified Eagle Medium) culture medium, trypsin, phosphate buffered saline (PBS), double antibody, fetal bovine serum (Fetal Bovine Serum), lipopolysaccharide (LPS), and DCFH-DA fluorescent probe.
[0060] 2.4 Experimental plan
[0061] 2.4.1 Grouping and Control
[0062] TM-1 dose groups: 0.01%, 0.05% and 0.1% TM-1 + 1 μg / mL LPS in DMEM medium (10% FBS).
[0063] Control information: ① Blank control group: DMEM culture medium (10% FBS), ②) Model control group: DMEM culture medium (10% FBS) with 1 μg / mL LPS.
[0064] 2.5 Experimental methods
[0065] 2.5.1 Cell culture
[0066] The cryopreserved HSF cells were revived and seeded into a cell culture flask at an appropriate density, and DMEM medium (10% FBS) was added and cultured in a cell culture incubator at 37° C. and 5% CO 2 (carbon dioxide).
[0067] 2.5.2 Cell seeding
[0068] After washing HSF cells in the logarithmic growth phase twice with PBS, trypsin was added for digestion, DMEM (10% FBS) was added to terminate the digestion, centrifuged, the supernatant was discarded, and DMEM medium (10% FBS) was added to prepare cell solution. 2 mL of cell suspension was seeded in a 35 mm culture dish and placed in a cell culture incubator for culture.
[0069] 2.5.3 Flow cytometry detection of reactive oxygen species
[0070] Fresh culture medium was added to the blank control group, culture medium containing LPS was added to the model control group, and culture medium containing LPS and the test substance was added to the sample group. After the addition of samples, the cells were placed in an incubator for 24 hours. Then, they were washed 3 times with PBS, and 1 mL of DCFH-DA (1:1000) dye prepared in DMEM (10% FBS) was added, incubated at 37°C in the dark for 30 minutes, and then washed 3 times with PBS. The level of ROS produced by the cells was observed under a fluorescence microscope.
[0071] The calculation formula of ROS generation rate is as follows:
[0072] ROS generation rate (%) = [ROS relative fluorescence intensity (sample group) - ROS relative fluorescence intensity (blank group)] / ROS relative fluorescence intensity (blank group) * 100%
[0073] 2.5.4. Data Statistics
[0074] GraphPad Prism 8.0 software was used to statistically process the data. The experimental data were expressed as mean ± SEM, and the data were analyzed using statistical methods such as t-test or one-way analysis of variance.
[0075] 2.5.5 Judgment basis, see Table 1
[0076] Table 1 Judgment basis
[0077]
[0078] 2.6. Test results
[0079] The effect of 0.01%, 0.05% and 0.1% TM-1 on the ROS production rate of HSF cells, the ROS production rate of the model control group was 253.82±17.67%, which was 253.82% higher than that of the blank control group (0.00±4.19%) (p<0.001), indicating that the HSF cell oxidative stress model was successfully established (very significant). Under the same conditions, the ROS production rate of HSF cells after treatment with 0.01%, 0.05% and 0.1% TM-1 was 78.34±7.05%, 74.27±17.22% and 44.43±8.57%, which was 175.48% (p<0.001), 179.55% (p<0.001) and 209.39% (p<0.001) respectively compared with the model control group, indicating that TM-1 has the ability to clear ROS under this experimental condition (very significant). The test results are shown in Table 2 and Figure 2 and Figure 3 .
[0080] Table 2 Effect of TM-1 on ROS production rate of HSF cells
[0081]
[0082] 2.7 Conclusion
[0083] After HSF cells were treated with 0.01%, 0.05% and 0.1% TM-1, the ROS production rates induced by LPS (1 μg / mL) were 78.34±7.05%, 74.27±17.22% and 44.43±8.57%, respectively, which were downregulated by 175.48% (p<0.001), 179.55% (p<0.001) and 209.39% (p<0.001) compared with the model control group, respectively. This shows that under this experimental condition, TM-1 has the ability to scavenge ROS (very significantly) and has anti-wrinkle and firming effects.
[0084] Example 3 Human efficacy evaluation test: moisturizing, firming, nourishing and anti-wrinkle efficacy.
[0085] 1. Test Purpose
[0086] Evaluation and testing of the moisturizing, nourishing and firming effects of TM-1.
[0087] 2. Test environment
[0088] Temperature: 21±1℃
[0089] Humidity: 50±10%RH 7.2
[0090] 3. Designated sample: a sample containing the peptide represented by formula TM-1.
[0091] Essence: an essence containing the peptide represented by formula TM-1.
[0092] 4. Usage:
[0093] 1) Clean your skin. Before using the serum, you need to clean your face to ensure that the skin pores are clean.
[0094] 2) After cleaning your face, apply toner evenly to ensure better results of the essence.
[0095] 3) Use essence. Take an appropriate amount of essence (usually 2 to 3 drops) and apply it evenly on the face, then gently press the face with your palms, gently pressing from bottom to top and from inside to outside to ensure that the essence is fully absorbed by the skin.
[0096] 4) Frequency of use: Use twice a day, once in the morning and once in the evening.
[0097] 5. Testing Process
[0098] D0:
[0099] 1) Subject information is registered, informed consent is understood and signed, and laboratory technicians screen subjects according to inclusion and exclusion criteria;
[0100] 2) The subject cleans the face with the designated sample and sits quietly in a laboratory at a temperature of 21±1°C and a humidity of 50±10% RH for 30 minutes;
[0101] 3) Test the basic values of the subjects' skin: VISIA image acquisition, Corneometer measures the moisture content of the skin stratum corneum, Cutometer measures the skin elasticity R2 value, skin firmness F4 value, skin stretch height R0 value, Glossymeter measures the skin glossiness, Ultrascan UC22 measures the thickness and density of the skin dermis;
[0102] 4) Laboratory technicians instruct subjects on how to use samples according to sample usage requirements and usage sites, and provide written test precautions and instructions for use;
[0103] 5) The subject receives the sample and leaves the laboratory.
[0104] D14:
[0105] 1) The subject cleans his face with the designated sample and sits quietly in a laboratory at a temperature of 21±1℃ and a humidity of 50±10% RH for 30 minutes;
[0106] 2) Skin data values of test subjects after using TM-1 samples for 14 days: VISIA image acquisition, Corneometer measurement of skin stratum corneum moisture content, Cutometer measurement of skin elasticity R2 value, skin firmness F4 value, skin stretch height R0 value, Glossymeter measurement of skin glossiness, Ultrascan UC22 measurement of skin dermis thickness and density;
[0107] 3) The subjects filled in the self-assessment questionnaire (after 14 days of use).
[0108] D28:
[0109] 1) The subject cleans the face with the designated TM-1 sample and sits quietly in a laboratory at a temperature of 21±1℃ and a humidity of 50±10% RH for 30 minutes;
[0110] 2) Skin data values of test subjects after using TM-1 samples for 28 days: VISIA image acquisition, Corneometer measurement of skin stratum corneum moisture content, Cutometer measurement of skin elasticity R2 value, skin firmness F4 value, skin stretch height R0 value, Glossymeter measurement of skin glossiness, Ultrascan UC22 measurement of skin dermis thickness and density;
[0111] 3) The subjects filled in the self-assessment questionnaire (after 28 days of use).
[0112] 5. Test items
[0113] Table 3 Test items
[0114]
[0115]
[0116] 6. Test Results
[0117] 6.1 Completion status of subjects
[0118] This study included 32 subjects with dry, rough, and loose facial skin, and finally completed 32 cases, with an age range of 26-54 years old, including 1 male and 31 females, with an average age of 42.00±7.75 years old. The test results are shown in Tables 4-15.
[0119] Table 4 Adverse reaction feedback during use
[0120]
[0121] Note: Refer to the 2015 edition of the "Technical Specifications for Safety of Cosmetics" for the grading standards for adverse skin reactions in human trials.
[0122] Result description: After using the TM-1 sample for 14 days, the skin reactions in the observed area were all level 0, and no adverse reactions occurred on the skin; after using the TM-1 sample for 28 days, the skin reactions in the observed area were all level 0, and no adverse reactions occurred on the skin.
[0123] Table 5 Water content of skin stratum corneum
[0124]
[0125] Result description:
[0126] Compared with before use, after using the TM-1 sample for 14 days, the moisture content of the stratum corneum of the skin increased by 94.00%, which was a significant difference.
[0127] Compared with before use, after using the TM-1 sample for 28 days, the moisture content of the stratum corneum of the skin increased by 107.86%, and the difference was significant.
[0128] Table 6 Elasticity R2 value
[0129]
[0130]
[0131] Result description:
[0132] Compared with before use, after using the TM-1 sample for 14 days, the skin elasticity R2 value increased by 9.07%, which was a significant difference;
[0133] Compared with before use, after using the TM-1 sample for 28 days, the skin elasticity R2 value increased by 10.36%, and the difference was significant.
[0134] Table 7 Skin stretch height R0 value
[0135]
[0136] Result description:
[0137] Compared with before use, after using the TM-1 sample for 14 days, the skin stretch height R0 value decreased by 11.85%, and the difference was significant.
[0138] Compared with before use, after using the TM-1 sample for 28 days, the reduction rate of the skin tensile height R0 value was 15.27%, and the difference was significant.
[0139] Table 8 Skin firmness F4 value
[0140]
[0141] Result description:
[0142] Compared with before use, after using the TM-1 sample for 14 days, the skin firmness F4 value decreased by 18.41%, which was a significant difference.
[0143] Compared with before use, after using the TM-1 sample for 28 days, the skin firmness F4 value decreased by 21.49%, and the difference was significant.
[0144] Table 9 Skin glossiness
[0145]
[0146] Result description:
[0147] Compared with before use, after using the TM-1 sample for 14 days, the skin glossiness increased by 59.23%, and the difference was significant.
[0148] Compared with before use, after using the TM-1 sample for 14 days, the skin glossiness increased by 66.02%, and the difference was significant.
[0149] Table 10 Skin dermis thickness
[0150]
[0151] Result description:
[0152] Compared with before use, after using the TM-1 sample for 14 days, the thickness of the dermis layer increased by 12.62%, with no significant difference;
[0153] Compared with before use, after using the TM-1 sample for 28 days, the thickness of the dermis layer of the skin increased by 12.79%, which was a significant difference.
[0154] Table 11 Skin dermis density
[0155]
[0156] Result description:
[0157] Compared with before use, after using the TM-1 sample for 14 days, the density of the dermis layer increased by 49.44%, which was a significant difference;
[0158] Compared with before use, after using the TM-1 sample for 28 days, the density of the dermis layer of the skin increased by 62.92%, and the difference was significant.
[0159] Table 12 Linear light intensity
[0160]
[0161] Result description:
[0162] Compared with before use, the improvement rate of linear light intensity of TM-1 sample after 14 days of use was 14.94%, and the difference was significant.
[0163] Compared with before use, the improvement rate of linear light intensity of TM-1 sample after 28 days of use was 36.17%, and the difference was significant.
[0164] Table 13 Skin color uniformity
[0165]
[0166]
[0167] Result description:
[0168] Compared with before use, after using the TM-1 sample for 14 days, the skin color uniformity was improved by 0.54%, which was a significant difference;
[0169] Compared with before use, after using the TM-1 sample for 28 days, the uniformity of skin color was improved by 0.25%, with no significant difference.
[0170] Table 14 Area ratio of crow's feet
[0171]
[0172] Result description:
[0173] Compared with before use, after using the TM-1 sample for 14 days, the improvement rate of crow's feet area was 19.08%, which was a significant difference;
[0174] Compared with before use, after using the TM-1 sample for 28 days, the improvement rate of crow's feet area was 35.84%, and the difference was significant.
[0175] Table 15 Proportion of area of under-eye wrinkles
[0176]
[0177] Result description:
[0178] Compared with before use, after using TM-1 sample for 14 days, the area ratio of under-eye wrinkles increased by 29.44%, which was a significant difference.
[0179] Compared with before use, after using the TM-1 sample for 28 days, the area ratio of under-eye wrinkles increased by 43.60%, which was a significant difference.
[0180] Test Conclusion
[0181] 32 subjects with dry, rough and loose facial skin used the test sample TM-1 for 28 consecutive days. The results showed the following effects: Under this test condition, TM-1 has moisturizing, nourishing, firming and anti-wrinkle effects;
[0182] After completing the TM-1 test cycle, 100.00% of the subjects agreed that TM-1 was mild and non-irritating;
[0183] The safety assessment results show:
[0184] After using TM-1 for 28 days, 32 subjects showed no adverse skin reactions.
[0185] The above description is only a specific implementation mode of the present invention, but the protection scope of the present invention is not limited thereto. Those skilled in the art should understand that any changes or substitutions that can be easily thought of by those skilled in the art within the technical scope disclosed by the present invention are within the protection scope and disclosure scope of the present invention.
Claims
1. A modified peptide, It is characterized in that The modified peptide is represented by the formula TM-1 shown below:
2. An isolated or synthesized compound, It is characterized in that A peptide represented by formula TM-1 as claimed in claim 1, or a stereoisomer, a mixture of stereoisomers, a cosmetically acceptable salt or a pharmaceutically acceptable salt of the peptide represented by formula TM-1 as claimed in claim 1.
3. A method for preparing the modified peptide according to claim 1, It is characterized in that The steps include: Step 1: Substitution reaction of reactant 1-1 with methyl 3-aminopropionate to obtain intermediate 1-2; Step 2: adding intermediate 1-2 and lithium hydroxide to a mixed solution of tetrahydrofuran and water to react to obtain intermediate 1-3; Step 3: Dissolve the intermediate 1-3, N-hydroxysuccinimide and N,N'-diisopropylcarbodiimide in dichloromethane and react to obtain the intermediate 1-4; Step 4: Dissolve the intermediate 1-4, L-proline and triethylamine in ethyl acetate and react to obtain the intermediate 1-5; Step 5: Dissolve the intermediate 1-5, N-hydroxysuccinimide and N,N'-diisopropylcarbodiimide in dichloromethane and react to obtain the intermediate 1-6; Step 6: Dissolve intermediate 1-6, H-Dab(Boc)-OH and triethylamine in ethyl acetate and react to obtain intermediate 1-7; Step 7: Dissolve intermediate 1-7, benzylamine, EDCI and HOAt in ethyl acetate and react to obtain intermediate 1-8; Step 8: Add intermediate 1-8 to a mixed solution of dichloromethane and trifluoroacetic acid to prepare compound TM-1.
4. A method for preparing the modified peptide according to claim 1, It is characterized in that The lithium hydroxide in step 2 is replaced by sodium hydroxide or potassium hydroxide; and / or the dichloromethane in step 3 is replaced by N,N-dimethylformamide.
5. The method for preparing the modified peptide according to claim 4, It is characterized in that The temperature of the substitution reaction in step 1 is 30° C.-50° C., and the stirring reaction is for 6-8 hours.
6. The method for preparing the modified peptide according to claim 4, It is characterized in that The volume ratio of tetrahydrofuran and water in step 2 is 10:
1.
7. The method for preparing the modified peptide according to claim 4, It is characterized in that The volume ratio of dichloromethane to trifluoroacetic acid in the mixed solution of step 8 is 2:
1.
8. The method for preparing the modified peptide according to claim 4, It is characterized in that The molar ratio of the reactant 1-1 in step 1 to methyl 3-aminopropionate is 1:1.0-1.
3.
9. A cosmetic composition, It is characterized in that It contains the peptide represented by formula TM-1 as claimed in claim 1, or contains the stereoisomer, mixture of stereoisomers, cosmetically acceptable salt or pharmaceutically acceptable salt of the peptide represented by formula TM-1 as claimed in claim 2.
10. A pharmaceutical composition, It is characterized in that It contains the peptide represented by formula TM-1 as claimed in claim 1, or contains the stereoisomer, mixture of stereoisomers, cosmetically acceptable salt or pharmaceutically acceptable salt of the peptide represented by formula TM-1 as claimed in claim 2.
11. Use of the peptide represented by formula TM-1 as claimed in claim 1 in a cosmetic composition or a pharmaceutical composition.
12. Use of the isolated or synthesized compound according to claim 2 in a cosmetic composition or a pharmaceutical composition.
